Nanoparticle abraxane possesses impaired proliferation in A549 cells due to the underexpression of glucosamine 6-phosphate N-acetyltransferase 1 (GNPNAT1/GNA1)

Abraxane (Abr), a US Food and Drug Administration-approved albumin-bound nanoparticle applied for the treatment of non-small-cell lung cancer, has been reported to be more effective than paclitaxel (PTX). To further understand the molecular mechanisms that produce this superior drug efficacy of Abr,...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhao, Minzhi, Li, Haiyun, Ma, Yan, Gong, He, Yang, Shu, Fang, Qiaojun, Hu, Zhiyuan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2017
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5338994/
https://www.ncbi.nlm.nih.gov/pubmed/28280335
http://dx.doi.org/10.2147/IJN.S129976

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5338994/
https://www.ncbi.nlm.nih.gov/pubmed/28280335
http://dx.doi.org/10.2147/IJN.S129976

Ejemplares similares